Navigation Links
FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
Date:2/28/2008

generalized social anxiety

disorder. J Clin Psychopharmacol. 2004;24:118-125.

(2) Hollander E, Koran LM, Goodman WK, et al. A double-blind,

placebo-controlled study of the efficacy and safety of

controlled-release fluvoxamine in patients with obsessive-compulsive

disorder. J Clin Psychiatry. 2003;64:640-647.

(3) LUVOX CR Prescribing Information. Jazz Pharmaceuticals, Inc., Palo

Alto, CA;2008.

(4) Westenberg HGM, Stein DJ, Yang H, et al. A double-blind

placebo-controlled study of controlled release fluvoxamine for the

treatment of generalized social anxiety disorder. J Clin

Psychopharmacol.2004;24:49-55.

(5) American Psychiatric Association. Diagnostic and Statistical Manual

of Mental Disorders, 4th ed, revised. Washington, DC: American

Psychiatric Association; 2000.

(6) Kessler RC, et al. Arch Gen Psychiatry. 2005; 62:593-602/ NIMH

Website:

http://www.nimh.nih.gov/health/publications/the-numbers-count-mental-

disorders-in-america.shtml#Anxiety, Date accessed December 14, 2007.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old
2. U.S. Court Approves AK Steels VEBA Health Care Settlement With Middletown Works Retirees
3. Securian Board Approves 8 Officer Promotions
4. MGT Capital Investments, Inc. Approves Share Buyback Program
5. Kaiser Permanente Approves $29 Million in Community Benefit Grants
6. Otter Tail Corporation Reports Record Revenues and Net Income From Continuing Operations for 2007; Earnings Per Share of $1.78; Board Approves Dividend Increase
7. Pennsylvania Attorney General Approves Vincentian Collaborative System-Marian Manor Integration
8. FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11
9. FDA Approves Additional Indication for Astellas MYCAMINE(R)
10. FDA Approves Labeling Change for Non-Drowsy CLARITIN(R)
11. FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... York, NY (PRWEB) , ... July 01, 2015 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – today announced that they will welcome four new members to their ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... a new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. Construction of ... the DIC Group’s U.S. Spirulina* production base, began in May 2014. After commissioning, ...
(Date:7/1/2015)... ... July 01, 2015 , ... OncLive® ... Hospital Corporation of America (HCA), as it further expands its Strategic Alliance Partnership ... , With this new partnership, OncLive’s editorial and marketing teams will collaborate with ...
(Date:7/1/2015)... ... July 01, 2015 , ... The 28th annual Charity Horse Show ... July 11, 2015, at 6 p.m. in Pugh Bourne Park, 343 Oakfield Road. The ... a petting zoo, an Elvis impersonator, a silent auction and concessions. , Horses and ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... lead author Lisa Stolzenberg, a Professor in FIU’s School of International and Public ... to 17 years who participated in the National Survey on Drug Use and ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2
... Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a ... Drug Application (NDA) for oxybutynin,chloride topical gel (OTG), ... Food,and Drug Administration (FDA). Watson is seeking marketing ... for the treatment of,overactive bladder (OAB)., OTG ...
... Be Medically Necessary, March of Dimes Says, WHITE ... all of the increase in U.S. singleton preterm births,according ... data., Between 1996 and 2004 there was an ... of those infants were delivered by a cesarean,section, (c-section), ...
... Attorney General Michael,B. Mukasey will deliver the keynote address ... remarks on Justice,Department nationwide efforts to combat healthcare fraud ... on WEDNESDAY, MAY 28, 2008., WHO: Attorney General ... WEDNESDAY, MAY 28, 2008, 1:00 P.M. EDT, ...
... a Tucson, Arizona,based medical device company, announced today ... $1.65 million. The financing has been,provided by Mesa ... San,Diego, Phoenix and Washington D.C., Medipacs Inc. ... with,the tremendous response by interested investors in our ...
... avoid the routine use of antioxidant supplements during radiation ... benefits of therapy, researchers concluded in a commentary published ... National Cancer Institute . , Radiation and many chemotherapy ... that damage DNA and proteins. Therefore, there is a ...
... uncovered a completely unexpected way that the brain repairs nerve ... to nearby neurons. , Astrocytes are a type of support ... their roles is to chew up damaged nerves during brain ... , Roger Chung and colleagues have now found that ...
Cached Medicine News:Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 2Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 3Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 4Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 5Health News:C-Sections a Critical Factor in Preterm Birth Increase 2Health News:Antioxidant supplements may lessen benefit of radiation and chemotherapy 2
(Date:7/1/2015)... 2015 According to a new ... Product (Natural & Synthetic, Fibrin, Collagen, Gelatin, Cyanoacrylate, Polymeric, ... Global Forecast to 2020", published by MarketsandMarkets, the global ... $2.64 Billion by 2020, growing at a CAGR of ... Browse 119 market T ables and ...
(Date:7/1/2015)... 24, 2015 Research ... of the "2015 Strategies in the Home/Self ... This new 175-page report provides analysis of ... (strips and meters), pregnancy, ovulation, and occult blood. ... requirements, technologies, and competitive profiles. The ...
(Date:7/1/2015)... FT LAUDERDALE, Florida , July 1, 2015 /PRNewswire/ ... manufacturer and marketer of innovative medical devices for the treatment ... it prevailed in a final opposition appeal hearing in the ... 482 - STENT HAVING HELICAL ELEMENTS (,482). The ,482 patent ... and has been upheld as a valid patent in amended ...
Breaking Medicine Technology:Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 2Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 3Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 42015 Strategies in the Home/Self Testing Market 2OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2
... Inc., (OTC Bulletin Board: NWCI ) a ... the second quarter ended June 30, 2010. More details ... 10-Q, filed with the Securities and Exchange Commission. ... made tremendous progress in commercializing our initial solution, QTinno™," ...
... Colo., Aug. 13 Mesa Laboratories, Inc. (Nasdaq: ... Directors has declared a regular quarterly cash dividend of ... September 15, 2010 to shareholders of record at the ... Mesa Laboratories develops, acquires, manufactures and markets electronic instruments ...
Cached Medicine Technology:NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 2NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 3NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 4NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 5NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 6NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 7NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 8NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 9NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 10
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
... used for in or out-of-office screenings and for ... from 20/15 to 20/200, two rows of spatial ... driver's scene. , ,The test is very useful ... acuity score, a functional acuity score and a ...
... face is the most widely used contrast sensitivity ... four (4) rows of sine-wave gratings. At the ... these gratings test the spatial frequencies of 3, ... a full contrast sensitivity curve, which is very ...
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
Medicine Products: